Oura Is Going Public on the Wellness Exemption

Oura filed to go public on September 3, with a planned Nasdaq listing under OURA and Goldman Sachs, Morgan Stanley and J.P. Morgan on the cover. The numbers are the kind most device companies never see: $1.21 billion in revenue for the nine months to June 30, up 74%; $974 million of it hardware, $240 million recurring membership; a 55% gross margin; $60.8 million in net income. Paid members doubled in a year to 5.0 million. The Wall Street Journal has reported a valuation north of $11 billion.

Buried in the risk factors is the sentence that matters for this audience. Oura markets its products as general wellness tools it believes are not subject to FDA device requirements. Then it tells investors it expects features it introduces going forward to be regulated as medical devices.

That is not a hedge. It is the plan, and the company has been executing it in the open.

In January the FDA loosened its wellness guidance, giving wearables room to surface trends in measures like blood pressure without crossing into device territory. Oura moved in May: it shipped a nighttime blood pressure trend feature under the wellness exemption, one that deliberately shows no systolic or diastolic numbers, while running a separate IRB-approved study of an algorithm meant to flag hidden hypertension. That second feature is intended to go through FDA. As of June 30, the study had enrolled more than 350,000 participants.

Read that number the way a clinical-stage device company would. Oura recruited a hypertension study population larger than most registries by pushing a notification to people who had already paid $349 to $499 for the sensor and $5.99 a month for the app. Members wear the ring a median of 23 hours a day. Twelve-month paid retention is roughly 85%. The company holds nearly 42 billion hours of longitudinal biometric data. Evidence generation, for Oura, is a feature rollout.

This is the device commercialization sequence run backward. The standard playbook is intended use, then evidence, then clearance, then reimbursement, then a sales force, then scale. Oura built the installed base and the habit first, then the data, and now proposes to buy regulation one feature at a time, only where a cleared claim is worth more than a wellness one. Its partnerships with Dexcom, ResMed and Eli Lilly, which holds a SAFE note converting at the IPO, let it borrow clinical pathways without owning them. ResMed’s deal routes ring users with breathing disturbances toward a clinician, so Oura never has to claim it detects sleep apnea.

The wellness line cuts both ways, though, and the S-1 knows it. A proposed class action in the Northern District of California argues Oura’s sleep-stage accuracy is no better than a coin flip; the prospectus lists accuracy litigation as a standing risk. More than half of members report a chronic condition, and 80% of those say they use Oura data to inform decisions about it. The company presents that as a strength. A regulator reading intended use might not. And once Oura holds a cleared hypertension feature, every accuracy claim on the adjacent wellness features will be read against a clinical standard, whether or not the FDA asks.

There is also the capital structure. The filing shows a $985 million deemed dividend to preferred holders and a $742 million net financing outflow for the period, meaning early investors took substantial liquidity before public buyers arrive. Net income is real; the $924 million net loss attributable to common stockholders is an accounting artifact of that transaction.

For device operators, the uncomfortable takeaway is this. The largest new public company in health hardware this year has never submitted a 510(k), and it is walking into regulation from a position of five million paying users rather than toward it from a position of zero. Clearance-first sequencing is still the safe path for anything that goes inside the body. For anything that sits on it, Oura just filed the case that it may no longer be the fast one.

SPONSORED BY RŌG HEALTH

Most device companies don't fail on technology. They fail on sequencing.

The free Commercial Readiness Check from RŌG Health takes two minutes and scores your commercialization across six dimensions — where you’re strongest, where you’re exposed, and what to fix first. If you want help closing a gap, it’ll point you to the right starting place.

Take the Readiness Check →

Want to put your brand in front of 35,000+ medical device and med tech leaders each week? Contact us to learn more about advertising opportunities.

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

The theme this week is follow-through. Almost every story is the second chapter of something you already read: a cyberattack that was “contained” and is now a guidance cut, a $13.1 billion acquisition whose brand is being retired, a plant bought out of a competitor’s collapse that’s now closing, a spinout that has stopped being a spinout and started being a company. The announcement is never the story. What the company does eleven days, or two years, later is.

Put your brand in front of 35,000+ medical device and med tech leaders each week. Contact us to learn more about sponsorship opportunities.

8 things to watch this week:

1. 🔐 Boston Scientific says the cyberattack will hit Q3 and full-year results

A September 7 SEC filing says last month’s attack is “likely to have a material impact” on Q3 and full-year 2026, and that both guidance ranges are now “unlikely.” Manufacturing and shipping are largely restored, but the backlog will take time and only “some portion” of lost revenue will be recovered. Stryker held full-year guidance through its March attack; Boston Scientific is the first large-cap this year to concede the year to a breach — in a week that also brought a recall of Infinion CX spinal cord stimulator leads tied to 1,081 serious injuries.

Fierce Biotech

2. 🧭 Most device companies don’t fail on technology. They fail on sequencing.

The free Commercial Readiness Check from RŌG Health takes two minutes and scores your commercialization across six dimensions — where you’re strongest, where you’re exposed, and what to fix first. If you want help closing a gap, it’ll point you to the right starting place.

Take the Readiness Check →

Sponsored by RŌG Health

3. 🦾 Stryker signs a definitive agreement to acquire ZuriMED

Stryker is buying privately held ZuriMED and its commercialized FiberLocker System, which anchors a rotator cuff patch across the full patch-tendon interface rather than at suture points. Terms weren’t disclosed. This is a failure-mode acquisition, not a category acquisition: the target is the re-tear, and the product rides surgeon relationships Stryker already has. That’s the tuck-in profile every strategic says it wants.

Stryker

4. 💉 MiniMed files its first patch pump with the FDA and raises guidance

The Medtronic spinout posted Q1 revenue of $843 million, up 17%, raised full-year organic growth to 10.5%, and disclosed an FDA submission for MiniMed Fit — a tubeless pump with a 300-unit reservoir and up to seven days of wear, targeted for next summer — alongside completed pivotal enrollment for a fully closed-loop algorithm and CE mark for Flex. Read the Fit specs against Insulet: reservoir size and wear time are aimed at Type 2 patients on higher insulin volumes, where Omnipod’s lead is most exposed.

MedTech Dive

5. 🏷️ J&J MedTech is retiring the Shockwave Medical name

Effective October 1, Shockwave Medical becomes Johnson & Johnson MedTech and its IVL portfolio becomes “circulatory restoration solutions”; the name survives only on the products. J&J paid $13.1 billion in May 2024. Twenty-eight months is the shelf life of a category-defining brand inside the world’s second-largest device company. If you’re negotiating a sale and telling yourself the acquirer will “keep the brand,” this is what that looks like.

MassDevice

6. 🩻 GE HealthCare secures CE mark for Photonova Spectra photon-counting CT

The CE mark follows FDA clearance and Japanese approval in March, opening Europe for GE’s Deep Silicon detector platform. Silicon is the wager: a different detector material to differentiate in a segment Siemens has owned since the first photon-counting clearance in 2021. Three major markets in six months is the cadence of a company making up for arriving late.

Medical Device Network

7. ⚡ Abbott wins FDA approval for its dual-energy TactiFlex Duo ablation catheter

Duo delivers pulsed field and radiofrequency energy from one catheter, switchable mid-procedure; U.S. cases begin in the coming weeks. CEO Robert Ford has said Duo and Volt are the two products Abbott is counting on to regain EP share in the back half. J&J’s dual-energy catheter was approved in July, so the market has moved past “PFA or not” to “how many energies per catheter.” Single-modality PFA entrants now have a spec-sheet problem.

MedTech Dive

8. 🏭 Zoll is closing the California ventilator plant it bought from Vyaire

Zoll, part of Asahi Kasei, is shutting the Palm Springs plant it acquired in 2024 with select Vyaire ventilator assets; a WARN notice lists 78 employees affected. Two years is roughly how long the integration math on a distressed-asset deal takes to resolve, and it usually resolves toward the acquirer’s existing footprint. In a carve-out, the site is rarely part of what’s being bought.

MassDevice

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague who should be tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

Medtronic Just Paid $700 Million to Sell Someone Else's Robot

Medtronic will distribute a rival soft-tissue robot alongside Hugo in China, Singapore and Europe. Enovis, the same day, bought its robot outright.

Medtronic spent the better part of a decade and an undisclosed fortune building Hugo. On Tuesday, it announced it would put roughly $700 million into Cornerstone Robotics, a Hong Kong company whose Sentire system competes for the same soft-tissue procedures, and distribute that robot alongside Hugo in China, Singapore and Europe.

The structure matters. This is an investment plus distribution rights, not an acquisition. Cornerstone keeps ownership of the platform and its IP. Medtronic gets a second console to put in front of hospitals that, for whatever reason, don’t want its first one.

Sentire is not a science project. It won CE mark in May for general, gynecologic, thoracic and urologic surgery, was approved in China in 2024, and is cleared in Singapore. Cornerstone raised about $200 million last November and operates a 30,000-square-meter manufacturing facility in China. The system has dual-console capability and an immersive console architecture that Medtronic’s own release describes as “a familiar configuration” — industry shorthand for something that looks and feels like da Vinci.

Hugo, by contrast, is less than a year past its first U.S. clearance, in urology, with 510(k)s pending for general surgery and gynecology. It is installed in more than 35 countries, and Medtronic expects total procedures to pass 50,000 by fiscal year-end on roughly 250 installed units.

On the earnings call the same morning, an analyst asked CEO Geoff Martha whether the deal signaled doubt about Hugo. “It’s just the opposite,” Martha said, calling it “a global play” and “one of a number of investments we’re making in soft tissue.” Global robotic penetration, he noted, is still in the single digits, and in emerging markets closer to 1%.

Read those two facts together and the strategy is legible. Medtronic is not hedging Hugo. It is conceding that one platform, priced and configured one way, cannot capture a market this early and this fragmented. Hospitals in Shenzhen and hospitals in Stuttgart are not buying the same robot for the same reasons at the same price. The company’s release says it plainly: “flexibility across clinical settings, procedural needs, and economic models.” That last phrase is the one to underline. Economic models. The technology was never the binding constraint on robotic adoption. The capital cost, the service contract, the per-procedure consumables, the utilization math a CFO has to defend — those were.

The same day, Enovis chose the opposite instrument. The orthopedics company agreed to buy France-based eCential Robotics for €155 million upfront and up to €35 million in milestones. eCential built J&J’s Velys Spine robot. Enovis had already been collaborating with it; now it wants the roughly 50-person team in-house to ship a knee robot in late 2028 and a shoulder robot in 2029. CEO Damien McDonald told investors the rationale was “agility.” The market’s response was a 16.5% share-price drop, mostly on margin dilution.

Two companies, one day, two answers to the same question: when you’re behind in robotics, do you build, buy, or distribute? Enovis, with no robot and a competitive gap its own analysts call its most notable, bought the capability. Medtronic, with a robot and a global ecosystem already in place, bought the option to sell a second one without absorbing the platform risk.

Neither is obviously right. Enovis now owns the engineering but also owns 2027’s margin hit and two launch dates it has to hit. Medtronic keeps its balance sheet lighter but has to manage a sales force selling two competing consoles and explain to every Hugo customer why the other robot exists.

What both deals share is an admission that the era of the single flagship robot is ending before most of the flagships have fully launched. Intuitive built one platform and let the market come to it. Its challengers, arriving into a market where the incumbent already sets the terms, are discovering they may need several.

Medtronic also disclosed a smaller move Tuesday: up to $80 million into Pi-Cardia, a structural heart company, with an option to acquire. Same architecture. Stake first, ownership later, if the numbers hold.

For anyone building a device company: the largest strategics are increasingly structuring their commitments as options, not acquisitions. That changes what “a partnership with Medtronic” means when it shows up in a term sheet.

SPONSORED BY RŌG HEALTH

Most device companies don't fail on technology. They fail on sequencing.

The free Commercial Readiness Check from RŌG Health takes two minutes and scores your commercialization across six dimensions — where you’re strongest, where you’re exposed, and what to fix first. If you want help closing a gap, it’ll point you to the right starting place.

Take the Readiness Check →

Want to put your brand in front of 35,000+ medical device and med tech leaders each week? Contact us to learn more about advertising opportunities.

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

Last week was a lesson in dependencies. A single intrusion stopped one of the world's largest device makers from shipping product. A single component inside a heart-pump controller is now tied to three deaths. A single patent judgment attached a 6% royalty to eleven of a liquid-biopsy company’s products for the next seven years. An activist told a heart-failure implant maker that going it alone is the risk. And the administration is reportedly adding two deputy commissioners at the FDA — one of them for AI — to tighten its grip on the agency. The companies that had the better week were the ones that removed a dependency: Abbott got the first sensor that watches ketones so patients don’t have to, and Roche got a blood test that can stand in for a PET scan. Know what you’re leaning on. Know who controls it.

Put your brand in front of 35,000+ medical device and med tech leaders each week. Contact us to learn more about sponsorship opportunities.

8 things to watch this week:

1. 🔒 Boston Scientific’s ordering and shipping disrupted in cyberattack

Boston Scientific disclosed a cyberattack that has affected its ability to process and ship customer orders, describing a global disruption to operations in an SEC filing; the company identified the attack on Tuesday and has not said how long the disruption will last. Employees at its Cork, Ireland manufacturing facilities were sent home because they couldn’t work, and by Saturday the company said the unauthorized activity appeared limited to certain on-premise systems, with no impact to cloud-based systems, and that it is working with CrowdStrike. Stifel analysts flagged increased uncertainty around the company’s 2026 revenue, margin and EPS outlook. This is the fourth major medtech intrusion of 2026 after Stryker, Intuitive and Medtronic — and the first where the headline damage is a stopped shipping dock rather than stolen data. If your hospital customers are asking about your business-continuity plan this week, that’s why.

MedTech Dive

2. 🧭 Most device companies don’t fail on technology. They fail on sequencing.

The free Commercial Readiness Check from RŌG Health takes two minutes and scores your commercialization across six dimensions — where you’re strongest, where you’re exposed, and what to fix first. If you want help closing a gap, it’ll point you to the right starting place.

Take the Readiness Check →

Sponsored by RŌG Health

3. ❤️‍🩹 FDA flags recall of all Impella heart-pump controllers after three deaths

The FDA issued an early alert after Abiomed told customers to remove all Automated Impella Controllers from where they’re used or sold due to purge cassette recognition failures; as of August 17 the company had reported 37 serious injuries and three deaths. J&J says the issue appears in 0.2% of cases, that hospital inventory can keep being used to maintain continuity of care while replacements are scheduled, and that it will swap the purge flag and purge retainer components during annual preventive maintenance or through field-service outreach. Controller issues were tied to recalls in July, September, October (twice) and December 2025 and again in May, which means the company’s most important acquisition since 2022 has now spent more than a year in near-continuous field action. Watch how the language shifts from “correction” to “remove all.”

Cardiovascular Business

4. 🩸 Abbott wins FDA nod for the world’s first dual glucose-ketone sensor

Abbott received De Novo authorization for Libre Duo 10 Day, a dual-analyte sensor that continuously measures glucose and ketones, wearable for 10 days by people with diabetes ages two and up who take insulin or other glucose-lowering medications; it received CE mark in May. The company says it’s the first system to meet both the FDA’s iCGM standard and a new integrated continuous ketone monitoring standard, which establishes a benchmark for continuous ketone monitoring in the U.S. — in other words, Abbott didn’t just win a clearance, it helped write the special controls every follower will now have to meet. Integration with Beta Bionics’ iLet and Sequel’s twiist is expected by year-end, with Insulet and Tandem in 2027; William Blair expects the sensor to be most competitive in pediatrics once it’s pump-integrated, since Dexcom’s approved pediatric sensors are also 10-day. Abbott receives FDA nod for dual-analyte sensor | MedTech Dive +3

MD+DI

5. 🧠 FDA clears Roche’s Alzheimer’s blood test for rule-in and rule-out assessment

Roche’s Elecsys pTau217 plasma test is cleared for people 55 and older with signs of cognitive decline, used alongside clinical information to assess Alzheimer’s risk. Developed with Eli Lilly, it’s the first FDA-cleared single-biomarker blood test supporting both rule-in and rule-out assessment of amyloid pathology using the same cutoffs across primary and specialty care, and it runs on existing lab instrumentation without new hardware. Labcorp and Quest both plan to offer it. The strategic read: a test that can rule out in primary care changes who gets referred for PET and CSF workups — and who doesn’t — which matters to anyone selling into the anti-amyloid infusion channel.

MassDevice

6. ⚖️ Guardant ordered to pay $245M in DNA-sequencing patent dispute

A U.S. district court entered final judgment ordering Guardant Health to pay more than $245.2 million to TwinStrand Biosciences and the University of Washington, upholding a November 2023 jury verdict that Guardant willfully infringed two Duplex Sequencing patents; Guardant must also pay a 6% ongoing royalty on 11 products and services through patent expiry in March 2033. The covered products include Guardant360, Guardant Reveal and Guardant Shield, though Guardant says it will appeal, that updated versions of Reveal and Shield are excluded from the royalty order, and that it continues to challenge the patents at the USPTO. Execution of the judgment and royalty collection are stayed pending appeal. Six points of gross on your flagship products for seven years is a licensing negotiation you’d rather have had in 2019.

Medical Device Network

7. 📣 CVRx has an activist investor urging it to get acquired

Pointillist Family Office founder Jorey Chernett, who holds 5.5% of CVRx, publicly told the Barostim maker’s board it should sell to a large device company with an established heart-failure and EP sales force, national payer relationships to resolve the prior-authorization impasse, and a balance sheet to fund the pivotal work already underway — citing a second-quarter report in which the company cut revenue guidance and disclosed a DOJ civil investigation into sales and marketing practices. Shares had lost a third of their value in a month before the letter; the board says it’s open to constructive engagement, and Johnson & Johnson already owns 15.2%. The argument isn’t that the device doesn’t work — it’s that reimbursement, sales coverage and trial funding are a scale problem a $3 stock can’t solve alone. Expect that thesis to get applied to other single-product neuromod names.

MassDevice

8. 🏛️ HHS plans new FDA deputy commissioner roles for technology and drugs

HHS is planning to appoint two new deputy commissioners at the FDA — one for technology, including health and AI, and one for drugs — in what some in the administration view as a bid to exert greater influence over the agency; no final decisions or announcements have been made. Jared Seehafer, an FDA senior advisor and device-industry veteran who co-founded the compliance software company Enzyme, is the leading candidate for the technology role, which would oversee both the agency’s internal use of AI and its review of AI-enabled products. Both roles would report to commissioner nominee Heidi Overton, who still needs Senate confirmation. Put this next to the generative-AI discussion paper from two weeks ago: the docket closes October 19, and the person who may end up owning the answer is a device-software founder.

CNBC

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague who should be tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

The Order Desk Goes Dark, Again

Boston Scientific found something wrong in its network on Tuesday morning. By Wednesday it was telling the SEC that it could not reliably take or ship customer orders anywhere in the world, and that it did not know when it would be able to again.

The company’s statement is short. A cybersecurity incident affecting certain IT systems caused a network outage and disrupted operations, including “the ability to process and ship customer orders.” Incident response protocols are active, third-party forensics firms are in, and systems are coming back in phases. The 8-K adds the sentence investors were looking for and didn’t want: the timeline for full restoration is not yet known, and the company hasn’t determined whether the impact will be material. A spokesperson told Cybersecurity Dive the same thing. Shares fell nearly 6% before the open.

Nobody has said ransomware. Nobody has named a threat actor or an entry point. What the filing does say is enough: a $5.4-billion-a-quarter company that sells stents, valves, ablation catheters and left-atrial-appendage closure devices to hospitals that schedule procedures around delivery windows is, as of this writing, unable to promise delivery windows.

The industry has seen this movie once already this year. Stryker was hit on March 11. Its ordering, shipping and manufacturing systems went down for weeks and weren’t fully restored until the first week of April. When Q1 results came in, growth was 2.6% against a company that had posted 10% to 12% every quarter of the prior year. RBC estimated the miss at about $317 million in organic sales. CEO Kevin Lobo said some procedures were lost and some reps couldn’t get into hospitals, 40,000 laptops were wiped, and the company insisted no customers were. By the July call it was still working through an order backlog.

Stryker’s attack landed three weeks before quarter-end. Boston Scientific’s landed five weeks before its own. The arithmetic is not complicated.

It lands on a company that was already recalibrating. Boston Scientific cut its 2026 outlook in late July, trimming organic growth to 5%–6% from 6.5%–8% and adjusted EPS to $3.28–$3.32, after Watchman volumes came in soft as physicians bundled the implant into other procedures rather than scheduling it on its own. A restructuring program with $700 million to $800 million in charges was approved the same summer. Stifel’s note Wednesday was blunt about what the attack does to the model: “increased uncertainty regarding our 2026 revenue, margin, and EPS outlook,” with no clarity yet on how the company will quantify or communicate it.

Step back and the pattern is the story. Medical device makers went years without a meaningful operational cyber event. In 2026 alone, UFP Technologies, Stryker, Intuitive, Medtronic, iRhythm, AdaptHealth, Abbott, Cook Medical and Baylor Genetics have all disclosed incidents. Most were data breaches — employee records, customer contact lists, patient information — that the companies described as non-material to operations. Two were not. Two of the five largest pure-play device companies in the world have now had their order desks taken offline within six months of each other.

That changes the questions hospital procurement asks. Supply chain teams that spent 2022 and 2023 building dual-source plans for resins and semiconductors now have a second category of single point of failure to plan around, and it isn’t a factory. Expect resilience language — restoration SLAs, manual-ordering fallbacks, inventory buffers held at the customer — to start showing up in GPO negotiations the way cybersecurity attestations showed up in device labeling after the FDA’s 2023 premarket requirements.

For everyone below the top five, the lesson is sharper. Stryker and Boston Scientific will recover; they have the balance sheet, the backlog and the customer relationships to absorb a lost month. A commercial-stage company with one product, one ERP instance and a Q3 revenue target does not. The question is no longer whether your product can get through the FDA. It’s whether your revenue can survive three weeks without an order desk — and whether anyone in the building has actually rehearsed the answer.

Boston Scientific says it will post updates to its website. As of Thursday morning there were none.

SPONSORED BY RŌG HEALTH

Most device companies don't fail on technology. They fail on sequencing.

The free Commercial Readiness Check from RŌG Health takes two minutes and scores your commercialization across six dimensions — where you’re strongest, where you’re exposed, and what to fix first. If you want help closing a gap, it’ll point you to the right starting place.

Take the Readiness Check →

Want to put your brand in front of 35,000+ medical device and med tech leaders each week? Contact us to learn more about advertising opportunities.

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

Put your brand in front of 35,000+ medical device and med tech leaders each week. Contact us to learn more about sponsorship opportunities.

8 things to watch this week:

1. 🏛️ Trump taps White House aide Heidi Overton to run the FDA

President Trump nominated Dr. Heidi Overton — deputy director of the White House Domestic Policy Council, former America First Policy Institute health chief, and the architect behind the administration’s vaccine-schedule and food-pyramid moves — to fill the commissioner seat vacant since Marty Makary resigned in May. Senate HELP chair Bill Cassidy, whose committee runs the confirmation, immediately voiced “strong concerns” about her lack of managerial experience; with MDUFA VI headed to Congress in January and the agency still absorbing staff cuts, the question of who’s actually running CDRH’s parent just got a longer runway.

RAPS

2. 🤖 FDA floats “competency assessment” model for generative-AI devices

The FDA’s Digital Health Center of Excellence published a discussion paper proposing a two-axis risk framework and a premarket approach modeled on how physicians are trained and evaluated — non-clinical benchmarking plus clinical confirmation — along with risk-proportionate postmarket monitoring and first agency thinking on foundation models and agentic AI. Comments are due October 19 under docket FDA-2026-N-7874; if a large language model is anywhere in your product roadmap, the premarket path is being drawn right now and the docket is where you draw it.

FDA

3. 🧭 Most device companies don't fail on technology. They fail on sequencing.

The free Commercial Readiness Check from RŌG Health takes two minutes and scores your commercialization across six dimensions — where you're strongest, where you're exposed, and what to fix first. If you want help closing a gap, it'll point you to the right starting place.

Take the Readiness Check →

Sponsored by RŌG Health

4. 🧠 ARPA-H hands Siemens Healthineers $31M to build an autonomous stroke robot

Siemens Healthineers will receive up to $31.1 million over five years — plus a $5.4 million cost share of its own — to develop endovascular robotics that perform mechanical thrombectomy remotely and without direct human input, with Stryker signed on as sub-awardee under the two companies’ 2025 neurovascular partnership. The agency’s math is the story: only about 12% of 335,000 eligible U.S. stroke patients get thrombectomy each year, and more than half the population lives over an hour from a center that can do it. Autonomy isn’t the goal; distribution is.

Radiology Business

5. ⚖️ Applied Medical asks court to permanently restrict Medtronic’s hospital contracts

Six months after a federal jury hit Medtronic with $382 million in damages for bundling LigaSure below cost and locking Applied’s Voyant out of GPO contracts, Applied has moved for a permanent injunction that would bar Medtronic from penalizing hospitals — through pricing, rebates or contract terms — for buying or even trialing a competitor’s vessel sealer. Applied says it turned down a Medtronic offer to carve out Applied alone; if the court agrees the remedy should open the market rather than protect one supplier, every strategic with a bundled-contract playbook has a new template to read.

MD+DI

6. 🏭 Intuitive plans 316,000-square-foot instrument plant in Malaysia

Intuitive signed a lease with Penang Development Corp. for a facility in Bandar Cassia Technology Park that will manufacture da Vinci instruments and electromechanical components starting in 2028, with 1,200 jobs targeted by 2032. The company framed it as Asia Pacific demand, which is true; it’s also a second instrument-manufacturing base for a company whose Mexicali plant has carried a lot of tariff exposure, and a signal of where the next wave of medtech capex is landing.

MassDevice

7. 💵 CMS grants add-on payment for Aidoc’s foundation-model CT triage

Aidoc’s CARE Body CT Multi-Triage — 14 cleared indications flagged from a single foundation model — will be eligible for a Medicare New Technology Add-on Payment on qualifying fee-for-service inpatient cases starting October 1, for three years. Aidoc calls it the first NTAP for a broad, multi-finding AI built on a foundation model rather than a single-condition algorithm; if that architecture is now reimbursable, the economics of building “one model, many indications” just changed for everyone behind them.

Diagnostic Imaging

8. 🔁 Haemonetics wins back CSL’s U.S. plasma business four years after losing it

Haemonetics disclosed in an SEC filing that CSL Plasma will begin transitioning some of its U.S. collection centers to the NexSys PCS platform, reversing a 2022 non-renewal that cost Haemonetics roughly an eighth of its revenue and sent CSL’s 300-plus centers to Terumo. The deal is non-exclusive with no minimums, but shares jumped about 15% and Needham sees a potential $183–223 million in annual revenue if the switch goes all the way. A reminder that a lost anchor account isn’t necessarily lost; NexSys’ Persona Plus clearance earlier this year appears to have been the reopening.

MassDevice

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague who should be tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

The First Robot Licensed to Stick You.

The FDA did something on Tuesday that it has never done before: it authorized a machine to perform venipuncture on its own.

The device is the Aletta, built by Utrecht-based Vitestro, and the agency granted it marketing authorization through the De Novo pathway as the first standalone robotic device that can draw blood from a patient’s arm without hands-on operator intervention. A patient places their arm in the machine. The Aletta scans with near-infrared light and Doppler ultrasound to find a vein — and to confirm it isn’t an artery — then applies the tourniquet, preps the skin, inserts the needle, swaps collection tubes, and places the bandage. If it can’t find a suitable vein, it declines to try. If the patient moves too much, the needle detaches automatically and the draw stops.

A trained phlebotomist still initiates each session and supervises throughout. But here is the number that matters: one phlebotomist can oversee up to three Aletta devices at once. That ratio is the entire commercial thesis. Blood draws are among the most commonly performed procedures in American medicine, the phlebotomist shortage is real and worsening, and Vitestro is not selling a robot so much as selling a 3-to-1 conversion on scarce labor.

What should hold the attention of anyone who builds devices is how the FDA cleared it. The agency’s authorization rests on clinical data showing the Aletta achieves successful draw rates comparable to or better than trained human phlebotomists when it proceeds with a stick — demonstrated across patients with varying health statuses, self-reported difficult vein access, and varying skin tones. In pivotal testing, the device posted a 94.5% first-stick success rate, and 90% of patients reported pain equal to or less than a manual draw. The regulatory benchmark for an autonomous device, in other words, was the human it replaces. Expect that comparator design to become the template for every autonomous-care submission that follows.

The second structural detail is buried in the authorization itself. Alongside the De Novo, the FDA established special controls — labeling, performance, and clinical testing requirements that define a brand-new device category. Once those controls exist, competitors don’t need their own De Novo. They can reach the U.S. market through the 510(k) pathway, citing Aletta as the predicate class. Vitestro spent years and considerable capital being first; the reward is roughly a product cycle of runway before the door it opened admits everyone else. That is the standing bargain of the De Novo pathway, and this is as clean an example as the industry gets.

Vitestro appears to have priced that bargain in. The company raised $70 million in March expressly to fund the U.S. entry — a Series B whose investors include Labcorp Venture Fund, Mayo Clinic, and Sutter Health. Read that list again: a national reference lab and two major health systems, all of whom operate exactly the high-volume outpatient draw sites Vitestro says it will target first. The cap table is the distribution plan. The Aletta earned its CE mark in August 2024 and has been running in European hospitals since — meaning the U.S. launch arrives with operational evidence, not just trial data.

The Aletta will not take blood from your toughest stick, and it isn’t going into inpatient units yet — the authorization covers adults in outpatient settings, under supervision. But the categorical line it crossed doesn’t get uncrossed. The FDA has now written rules for machines that perform invasive procedures on their own, and it graded the first one against people.

SPONSORED BY RŌG HEALTH

Most device companies don't fail on technology. They fail on sequencing.

The free Commercial Readiness Check from RŌG Health takes two minutes and scores your commercialization across six dimensions — where you’re strongest, where you’re exposed, and what to fix first. If you want help closing a gap, it’ll point you to the right starting place.

Take the Readiness Check →

Want to put your brand in front of 35,000+ medical device and med tech leaders each week? Contact us to learn more about advertising opportunities.

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

Put your brand in front of 35,000+ medical device and med tech leaders each week. Contact us to learn more about sponsorship opportunities.

8 things to watch this week:

1. 🩻 Teledyne to acquire Varex Imaging for $1.1B

Teledyne is buying X-ray component maker Varex Imaging for $18.90 per share in cash — roughly $1.1 billion — folding Varex’s X-ray tubes, flat-panel and photon-counting detectors into its imaging portfolio, with close expected in early 2027. After a summer of private equity buying up the supply layer, this is a strategic buyer doing the same math: the components underneath the imaging systems are worth owning outright.

MPO Magazine

2. 🏛️ Industry backs MDUFA VI as patient groups push for postmarket teeth

At the FDA’s public meeting on the MDUFA VI draft agreement, industry voiced broad support for a deal that keeps user fees roughly flat — or lower — for U.S. firms, shifts higher establishment fees onto overseas companies, and swaps MDUFA V’s hiring targets for regular CDRH headcount reporting. Comments run through year-end with the package headed to Congress in January; if the structure holds, your FY2028–2032 submission budget just got materially more predictable.

MedTech Dive

3. 🧭 Most device companies don't fail on technology. They fail on sequencing.

The free Commercial Readiness Check from RŌG Health takes two minutes and scores your commercialization across six dimensions — where you're strongest, where you're exposed, and what to fix first. If you want help closing a gap, it'll point you to the right starting place.

Take the Readiness Check →

Sponsored by RŌG Health

4. 📲 Abbott and Google pair Lingo glucose data with AI coaching

Abbott’s over-the-counter Lingo CGM will integrate with the Google Health app under a multiyear partnership, feeding glucose trends into Google’s Gemini-powered Health Coach and anchoring one of the largest real-world metabolic health studies attempted, with app integrations rolling out later this year. The consumer-health land grab now runs through distribution partners, and Abbott just secured the biggest one available.

Fierce Biotech

5. 🫀 iRhythm buys VitalConnect for $287.5M to expand cardiac monitoring reach

iRhythm is acquiring wearable biosensor maker VitalConnect — $237.5 million in cash plus $50 million in stock — adding the VitalPatch and mobile cardiac telemetry capabilities that extend the Zio platform from ambulatory arrhythmia detection into inpatient and hospital-to-home monitoring, with close expected by year-end. A category leader paying up to close its own portfolio gap before someone else does.

Cardiovascular Business

6. 🎗️ FDA proposes down-classifying digital breast tomosynthesis from Class III to Class II

The FDA published a proposed order moving DBT systems from Class III premarket approval to Class II with special controls — performance testing, software validation, clinical image evaluation — clearing 510(k) as the path for a technology that’s carried the PMA burden since 2011, with comments due October 9. Fifteen years of PMA data bought the whole category a cheaper regulatory ticket; worth watching which device type the agency down-classifies next.

Federal Register

7. 🤝 Philips lifts Exor’s ownership cap to 22% in updated agreement

Philips will let its largest shareholder, the Agnelli family’s Exor, raise its stake from the previous 20% cap to 22% — with room to go higher pending supervisory board approval — while governance terms stay unchanged. Exor bought in at 15% during the depths of the Respironics fallout; deepening the position now is a bet that the 2026–2028 turnaround plan is real.

MassDevice

8. 🏥 GE HealthCare weighs sale of $3B Patient Care Solutions business

GE HealthCare is reviewing strategic options — including a sale — for Patient Care Solutions, its patient monitoring, diagnostic cardiology, maternal-infant care, and anesthesia unit, which posted a 13.5% revenue decline and negative margins last quarter while representing about 15% of company revenue. Pair this with item #5 and a picture forms: monitoring assets are changing hands, and the question is who’s a natural owner.

MD+DI

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague who should be tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

Abbott Built the Sensor. Google Owns the Screen.

The most consequential thing about a medical device is increasingly not the device.

On Tuesday, Abbott and Google Health announced a multiyear partnership that will route glucose data from Abbott’s Lingo biowearable into the Google Health app, where Google’s Gemini-powered Health Coach will convert it into recommendations on nutrition, activity, sleep, and recovery. The companies also plan a large real-world study integrating continuous glucose, wearable, laboratory, and survey data — one intended, in Abbott’s framing, to shape both future Lingo features and Google’s coaching engine. Integrations begin rolling out later this year.

Read as a product announcement, it’s unremarkable: two large companies improving an app. Read as an architecture decision, it’s a marker for where value in consumer-adjacent medtech is migrating.

Start with what each side brought. Lingo is a regulated product. The FDA cleared it in June 2024 alongside Libre Rio, as an over-the-counter continuous glucose monitor for adults 18 and older who don’t use insulin, and Abbott launched it in the U.S. that September. Every claim about what that sensor measures, and how accurately, went through a 510(k).

Google brought the surface. The Google Health app is the rebuilt Fitbit app, built on a 2021 acquisition that cost $2.1 billion, and Health Coach launched globally on May 19 as the anchor feature of a Google Health Premium subscription — $9.99 a month or $99 a year, and bundled free into Google’s AI Pro and Ultra tiers in more than 30 countries. Google’s own terms for that coach are explicit: the tools are not intended for medical purposes.

So the boundary now runs straight through the product. Abbott’s cleared sensor produces the number. An unregulated wellness coach tells the user what the number means and what to do about it. Nothing about that is unlawful — the general wellness carve-out is well established, and Abbott’s own Lingo app has always offered coaching. But the FDA reviewed a measurement, not an interpretation, and the interpretation is now the part the user actually pays for monthly.

The commercial consequence is sharper than the regulatory one. Abbott gains distribution into an installed base it could never have assembled through hellolingo.com, and a research dataset with real strategic value. What it gives up is the interface. A consumer who lives in the Google Health app and pays Google $9.99 a month has a relationship with Google; Lingo becomes a fourteen-day disposable input to that relationship, purchased on price and accuracy like any other component. Abbott is very good at winning on price and accuracy. That is still a different business than the one it was in on Monday.

Compare Dexcom’s move three weeks earlier. Dexcom was named the first participant in the FDA’s TEMPO pilot for digital health devices, where it will test an AI-enabled glucose program aimed at improving glycemic control. Same technology problem, opposite instinct: pull the AI layer inside the regulatory perimeter, accept the evidentiary burden, and keep the clinical claim — and the customer — in-house.

Neither is obviously right. Platform partnership buys reach immediately and cheaply. Regulated integration is slower and more expensive, but a cleared claim is defensible in a way that a coaching feature isn’t, and it keeps the recurring revenue at home.

What device leaders should take from this week is that the choice is now live in their category too, not just diabetes. Any company whose product generates a continuous data stream will eventually face it: be the sensor inside someone else’s experience, or own the experience and pay the regulatory freight. Abbott just made its call in public. The question worth asking in your next portfolio review is which side of that line your roadmap has quietly already chosen.

SPONSORED BY RŌG HEALTH

Most device companies don't fail on technology. They fail on sequencing.

The free Commercial Readiness Check from RŌG Health takes two minutes and scores your commercialization across six dimensions — where you’re strongest, where you’re exposed, and what to fix first. If you want help closing a gap, it’ll point you to the right starting place.

Take the Readiness Check →

Want to put your brand in front of 35,000+ medical device and med tech leaders each week? Contact us to learn more about advertising opportunities.

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

KKR took the industry’s largest pure-play contract manufacturer private. Teleflex handed its OEM business to two more private equity firms and watched it re-emerge with a new name. Solventum announced it’s shedding software to become a “true medtech company.” Add CMS locking every hospital in America into mandatory joint replacement bundles, and a pattern emerges: the layer between your product and your revenue — who builds it, who pays for it, who owns the plumbing — is being redrawn while everyone watches the product headlines. If your commercialization plan assumes the infrastructure of 2024, last week was your notice.

Put your brand in front of 35,000+ medical device and med tech leaders each week. Contact us to learn more about sponsorship opportunities.

8 things to watch this week:

1. 🏦 KKR inks $5.7B deal to take medtech manufacturer Integer private

KKR agreed to acquire Integer Holdings — one of the world’s largest medical device CDMOs, serving cardiovascular, neuromodulation, and cardiac rhythm management markets — in an all-cash deal at $127 per share, expected to close by year-end. When a critical supplier to nearly every major strategic goes private, its investment priorities, capacity decisions, and pricing move out of public view — worth a conversation with your supply chain team before someone else’s diligence becomes your disruption.

Fierce Biotech

2. 🔧 Teleflex closes $1.5B OEM sale; business rebrands as Ingenyx

Teleflex completed the divestiture of its OEM contract manufacturing business to Montagu and Kohlberg on Monday, with the newly independent company launching as Ingenyx under continuing CEO Greg Stotts. Teleflex nets roughly $1.25 billion after tax, earmarked for debt paydown and buybacks — and the second major contract manufacturer in the same news cycle now answers to private equity rather than public shareholders.

MPO Magazine

3. 🧭 Where does your commercialization actually stand? Two minutes to find out.

Device companies rarely fail on technology — they fail on sequencing. RŌG Health's free Commercial Readiness Check scores your readiness across six dimensions and shows where you're strongest and most exposed. If you want help closing a gap, it'll point you to the right starting place.

Take the Readiness Check →

Sponsored by RŌG Health

4. 🏛️ Medicare finalizes 2.3% hospital pay raise — and the first nationwide mandatory joint replacement model

CMS’s final FY 2027 inpatient rule delivers a 2.3% pay bump hospitals call inadequate — and finalizes CJR-X, the first mandatory, nationwide bundled payment model, covering hip, knee, and ankle replacement episodes starting January 2028 with $725 million in projected five-year savings. For ortho device makers, every hospital customer just became financially accountable for 90 days of episode cost — expect implant pricing, site-of-care, and post-acute utilization conversations to sharpen well before the start date.

MedTech Dive

5. 🦵 Smith+Nephew slashes revenue outlook as orthopedics stumbles

Smith+Nephew cut full-year revenue guidance from roughly 6% to 4% after U.S. knee implant revenue fell 7.2% in Q2, with hips reversing after four quarters of above-market growth and wound bioactives down double digits on reimbursement resets. Read items #4 and #5 together: U.S. ortho demand is softening at the exact moment Medicare is preparing to make every hospital accountable for what those procedures cost.

MD+DI

6. 🩸 FDA panel to review GRAIL’s Galleri multi-cancer blood test in September

The FDA’s Molecular and Clinical Genetics Panel will convene September 23 to review GRAIL’s PMA for Galleri, the multi-cancer early detection test, backed by data from 25,490 PATHFINDER 2 participants and over 70,000 from the NHS-Galleri trial. This is the highest-stakes advisory committee of the year in diagnostics: the panel will effectively set the evidentiary bar for an entire MCED category — and it comes months after Galleri’s UK trial missed its primary endpoint.

CLP Magazine

7. ⚠️ BD recalls vascular access system needles after 4 patient deaths

BD is recalling specific lots of its intraosseous vascular access needle sets after out-of-tolerance manufacturing dimensions left clinicians unable to remove the stylet — with 75 complaints, 45 serious injuries, and four deaths reported, all during out-of-hospital cardiac arrest resuscitations. The affected lots shipped over a 20-month window, a reminder that dimensional tolerance drift is a commercial risk, not just a quality metric.

MassDevice

8. 🧩 Solventum plans software separation to become ‘true medtech company’

Solventum will sell or spin off its $1.4 billion health information systems business — about 16% of revenue — following last year’s $4.1 billion filtration divestiture to Thermo Fisher, leaving a company focused on medsurg and dental. CEO Bryan Hanson explicitly left “portfolio optimization” on the table, which is 2026’s polite phrase for: nothing in the portfolio is safe if it dilutes the multiple.

MedTech Dive

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague who should be tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

The Implant Becomes a Line Item

CMS released its FY 2027 hospital inpatient payment rule late Friday afternoon, and the number the industry read was 2.3%. That’s the base rate increase for acute care hospitals — worth roughly $2.1 billion in additional payments, and a touch below the 2.4% the agency floated in April. Hospital trade groups called it inadequate. By Monday, that was the story.

The consequential part was somewhere in the other 2,700 pages.

In the same rule, CMS finalized the Comprehensive Care for Joint Replacement Expanded Model — CJR-X — the first mandatory, nationwide test of episode-based payment in Medicare’s history. Beginning January 1, 2028, essentially every acute care hospital paid under the inpatient prospective payment system becomes financially accountable for the total cost of a hip, knee, or ankle replacement: the procedure, the implant, the stay, and the first 90 days of recovery, including physical therapy and any related readmission. Hospitals in Maryland, those already participating in TEAM, and a narrow set of others are carved out. Everyone else is in, regardless of appetite. CMS projects $725 million in Medicare savings over five years.

The mechanism is not theoretical, and neither is its effect on implant pricing. The original CJR model ran from April 2016 through December 2024 across a limited set of metropolitan markets. In CMS’s own evaluation of that model, one participating hospital’s experience is described plainly: five orthopedic surgeons approached the hospital about a gainsharing arrangement, and the resulting agreement “motivated surgeons to negotiate a capped price with implant vendors.” The hospital went on to build two separate pricing tiers for implants. That is the entire model in miniature — put the hospital at risk, let it share the upside with the surgeons who choose the hardware, and the hardware gets cheaper.

CJR-X preserves that architecture and removes the geographic limit. What was a controlled experiment across a few dozen markets becomes the default national condition for lower-extremity joint replacement, in both inpatient and hospital outpatient settings. CMS says the predecessor saved Medicare more than $100 million while holding quality steady, which is the agency’s stated basis for scaling it. Hospitals had asked for more runway; they got some, with the start date pushed from the proposed October 2027 to January 2028.

There is a second provision in the rule that almost nobody connected to the first. Under the Medicare Promoting Interoperability Program, CMS finalized the addition of a Unique Device Identifiers for Implantable Medical Devices measure — beginning with the EHR reporting period in calendar year 2027. Twelve months before hospitals are put at risk for the episode, they will be reporting, in structured form, exactly which implant went into which patient.

Episode cost accountability and implant-level data capture are arriving one year apart, in that order. Any hospital that wants to know which vendor’s construct correlates with shorter stays, fewer SNF discharges, and cleaner 90-day windows will have the record to run that analysis, and a direct financial reason to run it.

The same rule projects that new technology add-on payments will rise by roughly $779 million in FY 2027, driven by new approvals. Both things are true at once: Medicare is paying more for genuinely novel technology while systematically compressing the economics of the mature, high-volume procedure. The reward for differentiation is going up. The tolerance for undifferentiated premium pricing is going down.

For commercial teams in orthopedics, the practical consequence is that the buyer changes before the rule does. Value analysis committees begin modeling 2028 episode targets during 2027 contracting cycles, and the contract that gets signed next year is the one that has to survive the model. A sales argument denominated in the procedure — better fixation, faster OR time, surgeon preference — is now being evaluated against a denominator that runs 90 days past discharge and includes a skilled nursing facility the vendor has never set foot in.

The companies that will hold price are the ones that can put evidence against that denominator. Not a claim about it. Evidence. There are roughly eighteen months to generate it.

The FY 2027 IPPS final rule (CMS-1849-F) is available in the Federal Register. MedTech Dive covered the payment rates, and a client alert from counsel walks through the hospital-side alignment requirements.

SPONSORED BY RŌG HEALTH

The gap you can't see is the one that costs you.

Most device companies don’t fail on technology — they fail on sequencing. RŌG Health’s free Commercial Readiness Check takes two minutes and shows you where your commercialization is strongest and where it’s exposed, across six dimensions. If you want help closing a gap, it’ll point you to the right starting place.

Take the Readiness Check →

Want to put your brand in front of 35,000+ medical device and med tech leaders each week? Contact us to learn more about advertising opportunities.

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

Boston Scientific put a $700–800 million number on fixing its own cost structure. Stryker spent the quarter buying back the month a cyberattack took from it. The FDA raised submission fees nearly 10% and the FTC showed digital health companies what non-compliance costs. Meanwhile, the companies with balance sheets kept converting cash into position — MiMedx nearly doubling its surgical business in one stroke, Medtronic writing another venture check in electrophysiology, Abbott turning a partner’s FDA approval into a portfolio play. Last week wasn’t about who has the best technology. It was about who can afford the entry fee.

8 things to watch this week:

1. 🩸 FDA approves Freenome’s blood-based colorectal cancer test, with Abbott set to sell it

The FDA approved SimpleScreen CRC, Freenome’s blood-based colorectal cancer screening test, which Abbott will exclusively commercialize in the U.S. beginning this fall — triggering a $100 million milestone payment to Freenome under their 2025 agreement. The strategic tell: Abbott now sells both Cologuard and a blood test, and analysts expect it to position SimpleScreen for patients who refuse or never complete the stool test — a portfolio answer to screening drop-off, and a direct shot at Guardant’s Shield.

Fierce Biotech

2. 📉 Boston Scientific launches $800M restructuring, cuts 2026 guidance a second time

Boston Scientific approved a restructuring plan expected to cost $700–800 million in pre-tax charges, eliminate positions, and cut roughly $500 million in annual expenses by 2029 — then lowered its 2026 sales and earnings outlook days later on the Q2 call. Watchman and electrophysiology remain the drag, and management doesn’t expect either to improve soon. When the industry’s best-executing large cap of the last three years starts paying to shrink, the PFA share war has officially become expensive for everyone.

MD+DI

3. 🧭 Where does your commercialization actually stand? Two minutes to find out.

Device companies rarely fail on technology — they fail on sequencing. RŌG Health's free Commercial Readiness Check scores your readiness across six dimensions and shows where you're strongest and most exposed. If you want help closing a gap, it'll point you to the right starting place.

Take the Readiness Check →

Sponsored by RŌG Health

4. ⚖️ FTC sues Hims & Hers over health data sharing and billing practices

The FTC, joined by Utah and Los Angeles County, sued the telehealth giant July 29, alleging it shared sensitive health information with advertising platforms including Meta and Snap despite privacy-forward marketing, and deceived customers on billing and cancellation. The agency has already gone after Cerebral, GoodRx, and BetterHelp on similar grounds — any device or digital health company running ad pixels against patient-facing funnels should read this complaint as addressed to them.

MedTech Dive

5. 🤝 MiMedx to acquire Sanara MedTech for $350M

MiMedx agreed to acquire Sanara MedTech in a $350 million cash-and-stock deal at $35 per share — a 46% premium — combining its surgical portfolio with Sanara’s wound care and bone fixation technologies, including the FDA Breakthrough-designated OsStic bioadhesive slated for 2027 launch. The company expects the deal to nearly double its surgical revenue. Mid-cap consolidation in regenerative surgery is accelerating while the megacaps are distracted elsewhere.

MPO Magazine

6. 🏭 Stryker posts Q2 beats as cyberattack recovery drags into Q3

Stryker reported $6.6 billion in Q2 revenue, up 9.4%, and narrowed its guidance as it continues digging out from the March cyberattack that halted order processing, shipping, and manufacturing for nearly a month — CEO Kevin Lobo told investors the order backlog should reach a manageable level by the end of Q3. Five months after the breach, the incident is still shaping quarterly results — the clearest case study yet of what operational cyber risk actually costs a device manufacturer.

MassDevice

7. ❤️ Medtronic leads $37M Series C in AFib mapping startup CoreMap

Medtronic led an oversubscribed $37 million Series C for CoreMap, whose ultra-high-resolution electrode technology visualizes AFib activity that conventional mapping systems miss — the investment comes just weeks after Medtronic backed thrombectomy startup RapidPulse. The pattern is now unmistakable: rather than acquiring outright, Medtronic is seeding the next generation of cardiovascular technology with minority checks and waiting to see what proves out.

Cardiovascular Business

8. 🏛️ FDA raises FY 2027 device user fees, with registration costs up nearly 21%

The FDA set its FY 2027 MDUFA base revenue at $418 million, a 14% jump from FY 2026, with most submission fees rising about 10%; annual establishment registration fees climb nearly 21%. The new rates take effect October 1. For smaller companies budgeting 510(k)s and PMAs into next year, the regulatory line item just got materially bigger — worth re-running the submission timeline math now, not in Q4.

RAPS

Put your brand in front of 35,000+ medical device and med tech leaders each week. Contact us to learn more about sponsorship opportunities.

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague who should be tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

A Rebate Is Not a Recovery

Three of the largest device makers in the world reported second-quarter results in the last 48 hours, and all three booked money back from the U.S. government.

GE HealthCare recognized $129 million in International Emergency Economic Powers Act tariff refunds, lifting net income to $561 million from $486 million a year earlier. Philips booked €186 million, roughly 4.2 percentage points of its 16.4% adjusted EBITA margin. Boston Scientific recognized about $80 million in cost of products sold, which CFO John Monson told analysts represents substantially all of what the company expects to receive.

The money traces back to February 20, when the Supreme Court held 6–3 that IEEPA does not authorize the president to impose tariffs. The Court of International Trade subsequently ordered Customs and Border Protection to refund approximately $165 billion in duties collected across more than 53 million entries, and directed CBP to build an automated system to process them. Treasury Secretary Scott Bessent called the prospect “the ultimate corporate welfare” and predicted years of litigation. The checks cleared in about five months.

What matters for operators is not that the money arrived. It is what each company did with it in the disclosure.

GE HealthCare drew the sharpest line. Of the $129 million, the company excluded $106 million — the portion relating to 2025 duties — from adjusted figures entirely, keeping only $23 million, about four cents a share, in adjusted results. Then it reaffirmed full-year guidance without change. The underlying quarter carried its own weight: organic orders up 11.1%, backlog at a record $23.9 billion, book-to-bill of 1.15. Shares rose roughly 12% premarket.

Philips took the opposite approach and raised guidance on the strength of the refund, lifting its full-year adjusted EBITA margin target to 13.5%–14.0% from 12.5%–13.0% and free cash flow to €1.5–1.7 billion. The company acknowledged that without the one-time benefit, underlying profitability would have declined slightly on cost inflation. Investors noticed. The stock fell 9% Tuesday to its lowest level in a year, pressured further by new Chinese rules routing public hospital device purchases through a centralized state program.

Boston Scientific presented the cleanest illustration of the gap between the two numbers. Organic revenue grew 7%, at the high end of guidance. Adjusted EPS of $0.86 beat the range. And the company still cut its full-year organic growth outlook to 5%–6%, citing a slowdown in Watchman and competitive pressure in U.S. electrophysiology, while announcing a restructuring targeting roughly $500 million in run-rate savings by the end of 2029. The refund landed in the same quarter as a decision to take out half a billion dollars of cost.

The through-line: a tariff refund is a balance-sheet event that arrives dressed as an operating one. It flows through cost of goods or income from operations, it expands margin, and it does so with no relationship whatsoever to whether the underlying business improved. Every finance team in the industry now has one quarter in which the reported margin and the earned margin diverge, and a decision to make about how visible to render the difference.

The second point is more durable. The refunds close out a tariff regime that no longer exists — but the tariffs do. Within a day of the February ruling, the administration moved to replace the invalidated levies with a 10% across-the-board tariff under Section 122 of the Trade Act of 1974, and new duties covering 60 trading partners took effect this month. Philips said plainly that elevated tariff costs continue to pressure operations. GE HealthCare cited geopolitical instability weighing on costs, supply chains, and logistics.

So the industry got its money back for duties paid under a statute the Court rejected, and is now paying comparable duties under statutes it hasn’t. The refund is not relief. It is a reconciliation of one legal theory, arriving in the middle of a cost structure that hasn’t changed.

For anyone building a 2027 plan on the back of this quarter’s margin, the useful question is which number the board is going to remember — the one that includes the refund, or the one that shows what the business actually did.

SPONSORED BY RŌG HEALTH

Where does your commercialization actually stand?
Two minutes to find out.

Device companies rarely fail on technology — they fail on sequencing. RŌG Health's free Commercial Readiness Check scores your readiness across six dimensions and shows where you're strongest and most exposed. If you want help closing a gap, it'll point you to the right starting place.

Take the Readiness Check →

Want to put your brand in front of 35,000+ medical device and med tech leaders each week? Contact us to learn more about advertising opportunities.

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

J&J’s Ottava cleared the FDA on July 22. That same day, Vicarious Surgical’s shareholders voted to liquidate a company that had raised more than $425 million. Read those two headlines together and you have the industry’s operating thesis for 2026: the barrier to entry in high-capital medtech categories is no longer the technology, it’s the balance sheet and the commercial infrastructure behind it. The same logic showed up everywhere last week — Tempus buying its way into tumor-informed MRD rather than building it, Labcorp leaning on an acquired genetics portfolio to go direct-to-consumer, Edwards waiting on a coverage decision that will do more for volume than any product launch. Scale is the entry ticket now. Everything else is execution.

8 things to watch this week:

1. 🤖 J&J’s Ottava wins FDA De Novo authorization, ending Intuitive’s soft-tissue monopoly

After nearly a decade of delays, J&J secured De Novo marketing authorization for the Ottava Robotic Surgical System across ten general surgery procedures — the first soft-tissue platform to integrate its arms directly into the OR table, occupying 30–50% less space than boom- or cart-mounted systems. J&J is running a controlled launch with select U.S. customers and deliberately entered through general surgery, the less-penetrated segment where Ethicon’s install base and relationships are strongest. Both Intuitive and Medtronic shares declined on the news.

2. ⚰️ Vicarious Surgical shareholders vote to dissolve the company

Shareholders approved an assignment for the benefit of creditors — an alternative to bankruptcy — for a robot developer that raised more than $425 million from investors including Bill Gates ahead of its 2021 SPAC-era IPO. The company failed to secure additional funding or find a buyer and employed 26 people as of March. Same category, same week, opposite outcome: capital depth and channel access are now the gating factors in robotics, not the elegance of the architecture.

MedTech Dive

3. 🧭 Where does your commercialization actually stand? Two minutes to find out.

Device companies rarely fail on technology — they fail on sequencing. RŌG Health's free Commercial Readiness Check scores your readiness across six dimensions and shows where you're strongest and most exposed. If you want help closing a gap, it'll point you to the right starting place.

Take the Readiness Check →

Sponsored by RŌG Health

4. 🩺 FDA names Dexcom the first participant in its TEMPO digital health pilot

CDRH selected Dexcom as the inaugural manufacturer in the Technology-Enabled Meaningful Patient Outcomes pilot, which pairs device oversight with real-world evidence generation and is explicitly tied to CMS Innovation Center’s ACCESS model — whose first cohort began this month. The Dexcom Glucose Health Program will combine G7 and Stelo data with nutrition, activity, sleep, and stress inputs. FDA says it’s still accepting statements of interest with no deadline, which makes this the clearest regulatory-plus-reimbursement on-ramp available to digital health right now.

MPO Magazine

5. ⚠️ FDA issues early alert as Boston Scientific pulls transcarotid catheter lots

Boston Scientific told customers on July 9 to stop using and return specific lots of the EnRoute Transcarotid Neuroprotection System and NPS Plus after reports of arterial sheath tip separation; the FDA posted its early alert Friday. One serious injury and no deaths have been reported, but retained tips may require endovascular or surgical retrieval, with embolism, stroke, TIA, restenosis, or thrombosis among the potential complications. The device came over in the $1.18 billion Silk Road Medical acquisition — a reminder that acquired product lines carry acquired quality histories.

Cardiovascular Business

6. 💓 Edwards posts strong TAVR quarter with a September coverage decision pending

Edwards raised its full-year outlook on strong structural heart performance, with TMTT revenue up roughly 47% year over year. The bigger catalyst is regulatory: CMS is expected to finalize its TAVR national coverage determination in September, and the draft policy opens a pathway to cover asymptomatic patients while modernizing heart-team requirements. PROGRESS data in moderate aortic stenosis follows at TCT this fall. For anyone modeling structural heart volume, September is the date that matters.

MedTech Dive

7. 🧬 Tempus to acquire Personalis for $1.5B, buying its way into tumor-informed MRD

Tempus agreed to pay $16.25 per share for the cancer-monitoring company, a 6% premium to the prior close and 28% to the unaffected 30-day VWAP, in a deal expected to close in late 2026 or early 2027. The strategic logic is straightforward — Tempus has been commercializing Personalis’ NeXT Personal test since 2023 and its own MRD capability isn’t tumor-informed, the methodology the market is converging on. Both stocks fell on the announcement, largely on the stock-based structure rather than the thesis.

MD+DI

8. 🧪 Labcorp launches a 163-gene direct-to-consumer hereditary risk panel

Marker by Labcorp analyzes 163 genes tied to more than 100 medically actionable conditions across hereditary cancer, cardiovascular, and metabolic categories, with licensed genetic counselors included and availability starting August 3 through Labcorp OnDemand. It’s the company’s first major consumer genetics product since absorbing Invitae’s portfolio in 2024, and Labcorp is explicitly positioning it against curiosity-driven DNA testing. The consumer channel is now a distribution strategy for clinical-grade diagnostics, not a novelty adjacent to one.

Fierce Biotech

Put your brand in front of 35,000+ medical device and med tech leaders each week. Contact us to learn more about sponsorship opportunities.

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague who should be tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

Who Could Afford to Be Late

Within about 24 hours this week, the surgical robotics field delivered two verdicts that read like opposite ends of the same story.

On Tuesday, shareholders of Vicarious Surgical voted to dissolve the company and hand its assets to a creditor trust — an assignment for the benefit of creditors, the orderly alternative to bankruptcy. On Wednesday, the FDA granted De Novo authorization to Johnson & Johnson’s Ottava, clearing the first table-integrated soft-tissue robot for general surgery in the United States.

Both programs ran years past their own timelines. The difference showed up in what happened next.

Vicarious was not a fringe player. Founded in 2014, it went public in 2021 through a SPAC merger that valued it at $1.1 billion, and it raised hundreds of millions from investors that included Bill Gates. Its single-port system — miniaturized arms and a camera threaded through one incision, built to put the surgeon inside the abdomen — was novel enough to become the first surgical robot ever to earn the FDA’s breakthrough device designation.

It also missed, repeatedly. The system slipped against its stated timelines. A planned clinical trial was scrapped. Parts of the design were outsourced to conserve cash. The company lost its NYSE listing earlier this year and moved to the over-the-counter market. When it went looking for fresh capital or a buyer this spring, it found neither. As of early March it employed 26 people. In its final filings, the board told shareholders they were unlikely to receive anything at all — even as terminated executives were set to collect severance packages north of half a million dollars each.

Ottava is the other end. J&J’s robotics ambitions run back through Verb Surgical and the acquisition of Auris Health, and Ottava itself was delayed repeatedly against publicly stated targets. But a parent that just beat $25 billion in quarterly sales does not face a going-concern deadline when a program runs long. It rewrites the date and keeps paying the engineers.

That comparison is worth exactly what it costs, which is not much. Almost nobody reading this is J&J, and “have a $400 billion parent” is not a strategy. The useful case sits between the two, and surgical robotics has already run it.

Asensus Surgical — formerly TransEnterix — hit the same wall Vicarious did. Its Senhance platform was commercial but small, its next-generation Luna system was years from clearance, and cash was the binding constraint. It did not liquidate. In August 2024 it was acquired by Karl Storz for $0.35 a share in cash. The technology found a home; more than 200 employees came along; the buyer talked publicly about accelerating Luna.

Twenty-two months later, Karl Storz ended development of the standalone platform, began phasing out Senhance, retired the Asensus brand, and filed notice of 108 layoffs in North Carolina. What it kept was the software engineering, the clinical data, and the AI work — folded into its own imaging and OR-integration roadmap.

So the three exits are not survive, get rescued, or die. They are: absorb the delay yourself, sell into someone who will decide later which parts of you were worth buying, or liquidate. Only the first is fully in your control, and only the largest companies in the industry have it.

This is the part worth sitting with. Asensus is the good outcome in that set, and the good outcome still ended with the platform discontinued and the brand retired. It preserved the people and the IP. It did not preserve the company’s plan. And the price — thirty-five cents — was set by a buyer who knew exactly how much runway was left on the other side of the table.

For anyone running a capital-intensive program on a regulatory timeline, that reframes the planning question. It is not how long the runway is against the current schedule; the current schedule is the optimistic case, and slippage is the base case, not the downside. The question is what your position looks like at the moment the money gets tight — because that moment is when the exit gets chosen, and whoever has cash at that point sets the terms.

Vicarious had the idea first. Asensus had a buyer. J&J had the room to be late. Three companies, one category, three different answers to the same missed deadline.

SPONSORED BY RŌG HEALTH

Where does your commercialization actually stand?
Two minutes to find out.

Device companies rarely fail on technology — they fail on sequencing. RŌG Health's free Commercial Readiness Check scores your readiness across six dimensions and shows where you're strongest and most exposed. If you want help closing a gap, it'll point you to the right starting place.

Take the Readiness Check →

Want to put your brand in front of 35,000+ medical device and med tech leaders each week? Contact us to learn more about advertising opportunities.

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

8 things to watch this week:

1. 🤖 Intuitive’s U.S. procedure growth hits a three-year low — and it’s naming names

Q2 beat on revenue and EPS, but U.S. da Vinci procedure growth slowed to 12% from 14%, and management pointed at two structural culprits: expired ACA enhanced-premium subsidies delaying deferrable surgeries, and GLP-1s pushing bariatric volume down high single digits. The company held its 13.5%–15.5% full-year procedure forecast but guided to the midpoint — and shares dropped double digits, because procedures drive everything downstream in this business model. If insurance-mix softness is real, Intuitive is the canary. Yahoo Finance + 3

MD+DI

2. 🩺 Abbott beats, raises guidance, and shrugs off the ACA worry entirely

Abbott topped Wall Street forecasts and raised full-year adjusted EPS guidance to $5.45–$5.60 — one quarter after cutting it on Exact Sciences dilution, with the March-closed Exact acquisition fueling more than 40% diagnostics growth. The strategic read: diversification is buying Abbott immunity from the exact demand question that just knocked Intuitive down — and management publicly rejected the idea that ACA enrollment declines are materially hurting medtech at all.

MassDevice

3. 🧭 Where does your commercialization actually stand? Two minutes to find out.

Most medical device companies don't stall because the technology is wrong. They stall because the sequencing is — launching before the market's ready, scaling before the evidence lands, chasing the next milestone before the last one is proven. RŌG Health's Commercial Readiness Check is a short diagnostic that maps where your commercialization actually stands right now, across the gaps that quietly derail otherwise strong programs. If you want help closing a gap, it'll point you to the right starting place.

Take the Readiness Check →

Sponsored by RŌG Health

4. 📉 J&J MedTech growth eases again as Abiomed drags on the quarter

J&J’s device unit posted another quarter of slowing sales growth, with Abiomed weighing on results — a slowdown the company attributed in part to physician response to third-party randomized trial data on Impella. The lesson for every company with a flagship franchise: independent evidence can reprice a market leader’s growth story faster than any competitor can.

Fierce Biotech

5. ⚠️ Medtronic pulls 102 lots of Harmony delivery catheters in Class I recall

Medtronic voluntarily recalled 102 lots of its Harmony delivery catheter system over a distal-tip detachment risk that could require endovascular retrieval or surgery — the FDA’s most serious recall classification, though no serious injuries or deaths had been reported as of mid-May. The valve itself isn’t affected. A reminder that in structural heart, the delivery system carries as much risk exposure as the implant. AOL

Fierce Biotech

6. 🦴 DePuy Synthes buys screwless spine implant maker ahead of its J&J spinout

DePuy acquired Expanding Innovations, whose expandable interbody cages use no screws, on undisclosed terms — strengthening its position in the expandable-cage segment and slotting into the Velys robotic platform as J&J prepares to spin the orthopedics business out. Portfolio-sharpening before a spinout is a familiar playbook: DePuy is building the standalone story it will pitch to public investors.

MedTech Dive

7. 🧠 RapidPulse raises $48M for stroke thrombectomy — with Medtronic co-leading

The Miami-based company closed a Series B for its next-generation aspiration technology for acute ischemic stroke, with Medtronic co-leading alongside TechWald and S3 Ventures. When a strategic co-leads a round in its own core category, read it as an option on future M&A — and a signal of where neurovascular incumbents think the technology curve is bending.

MassDevice

8. 🗓️ FDA hosts Wednesday town hall on human factors guidance — with an August 1 deadline attached

CDRH holds a town hall July 22 on its final guidance covering human factors information in marketing submissions, issued May 29 — and beginning August 1, updated eSTAR templates will prompt manufacturers to identify a Human Factors Submission Category and provide supporting information. If you have a 510(k), De Novo, or PMA in the pipeline, this is the week to get your regulatory team on the same page.

FDA

Put your brand in front of 35,000+ medical device and med tech leaders each week. Contact us to learn more about sponsorship opportunities.

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague who should be tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

Priced Not to Be Seen

The largest penalty ever imposed for dodging a merger filing belongs to the medical device industry as of Monday. The Federal Trade Commission announced a $12 million settlement with Edwards Lifesciences and Genesis MedTech over Edwards’ 2024 acquisition of JC Medical, the Genesis subsidiary developing a transcatheter valve for aortic regurgitation. Under the proposed final judgment, Edwards will pay $10 million and Genesis $2 million — the largest combined penalty in the history of the Hart-Scott-Rodino Act’s filing requirement, according to the agency.

The arithmetic at the center of the complaint is almost elegant. At the time of the deal, any transaction valued above $119.5 million had to be reported to federal antitrust regulators before closing. Edwards agreed to pay $115 million for JC Medical, plus milestone payments — $4.5 million under the line. It also agreed, at the same time, to make a $25 million investment in Genesis itself. Treated as separate transactions, neither required a filing. Treated as what the FTC alleges they were — a single acquisition with the price split across two agreements — the deal cleared the threshold comfortably and should have been reported before it closed.

What happened the next day is why regulators noticed. One day after closing on JC Medical, Edwards moved to acquire JenaValve Technology — JC Medical’s only competitor — for $945 million. That deal was large enough that Edwards had to file. The filing triggered an investigation, the investigation surfaced the structure of the JC Medical purchase, and the FTC sued to block JenaValve on the grounds that Edwards would otherwise own the only two U.S. companies with TAVR-AR devices in clinical trials. In January, a federal court granted a preliminary injunction after a six-day hearing, and Edwards walked away from JenaValve while disputing the ruling. Monday’s settlement closes out the remaining question: what it costs to have skipped the filing in the first place. Edwards and Genesis deny wrongdoing, and the judgment involves no admission of liability.

The money is not the interesting part. Twelve million dollars is a rounding error against Edwards’ balance sheet. The interesting parts are structural, and there are three of them.

First, the seller paid too. Genesis’ $2 million penalty establishes that both sides of a deal structured to avoid review carry exposure — a point antitrust lawyers flagged within a day of the announcement. For smaller companies negotiating an exit to a strategic, how the buyer wants to structure the consideration is no longer only the buyer’s problem.

Second, Edwards now operates under a bespoke leash. The judgment requires advance written notice to the FTC before Edwards acquires any interest in any firm that sells a TAVR-AR device in the U.S., is running U.S. clinical trials on one, or holds an investigational device exemption to start. In an entire category, Edwards has lost the thing every acquirer of sub-threshold companies takes for granted: the ability to close quietly.

Third, the timing. This lands in the middle of a running boom in medtech dealmaking — the strongest first half for sector M&A since 2022, by BioWorld’s tracking — much of it composed of exactly the kind of tuck-in acquisitions that fall below the reporting line. The threshold adjusts annually and most small deals will keep closing without review. But the substance-over-form logic here — that a side investment, a milestone schedule, or any contemporaneous consideration counts toward the real price — is now backed by a record penalty and a chairman promising that companies who “sneak deals through” should take notice.

For device companies on either side of an acquisition, the operative lesson is that the threshold was never a safe harbor. It was a reporting line. The FTC just demonstrated it knows the difference — and that it may learn about your last deal from your next one.

SPONSORED BY RŌG HEALTH

Where does your commercialization actually stand?
Two minutes to find out.

Device companies rarely fail on technology — they fail on sequencing. RŌG Health's free Commercial Readiness Check scores your readiness across six dimensions and shows where you're strongest and most exposed. If you want help closing a gap, it'll point you to the right starting place.

Take the Readiness Check →

Want to put your brand in front of 35,000+ medical device and med tech leaders each week? Contact us to learn more about advertising opportunities.

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

Two of the industry’s biggest names spent the week reshaping their portfolios in opposite directions — Roche muscling into sequencing, ResMed shedding software to fund its core — while the reimbursement map shifted underneath everyone with a sweeping CMS proposal and a landmark payer win for blood-based cancer screening. The counterweight was risk surfacing where the giants are most exposed: a Terumo aortic recall tied to three deaths, and Medtronic’s breach notification reaching nearly four million people. The throughline for operators: the same reach that drives growth now defines the downside, and quality systems, reimbursement strategy, and data governance are moving from back-office concerns to boardroom ones.

8 things to watch this week:

1. 🧬 Roche takes on Illumina with new NGS system

Roche launched Axelios 1, its long-teased sequencing platform built on new “sequencing by expansion” chemistry, priced at roughly $750K against Illumina’s NovaSeq X and targeting research labs first with a clinical path to follow. More than a decade after its failed hostile bid for Illumina, Roche is attacking the $7.3B market on price and speed rather than head-on — a reminder that in a mature category, the entry strategy matters as much as the technology.

Fierce Biotech

2. 💨 Resmed to sell software business MatrixCare for $490M to private equity firm

Resmed agreed to offload MatrixCare — a $220M-revenue post-acute EHR business it bought for $750M in 2018 — to Frazier Healthcare Partners, redirecting capital toward sleep, breathing, and connected home care. It’s a clean case study in portfolio discipline: a mature, slower-growing asset carved out so the core can compound faster, with proceeds funding buybacks rather than new bets.

MedTech Dive

3. 🧭 Where does your commercialization actually stand? Two minutes to find out.

Most medical device companies don't stall because the technology is wrong. They stall because the sequencing is — launching before the market's ready, scaling before the evidence lands, chasing the next milestone before the last one is proven. RŌG Health's Commercial Readiness Check is a short diagnostic that maps where your commercialization actually stands right now, across the gaps that quietly derail otherwise strong programs. If you want help closing a gap, it'll point you to the right starting place.

Take the Readiness Check →

Sponsored by RŌG Health

4. 🏛️ CMS targets 340B, site-neutral pay in 2027 outpatient rule

The CMS 2027 OPPS/ASC proposed rule, issued July 2, would deepen 340B drug payment cuts and push site-neutral payment into new outpatient categories — moves projected to pull billions from hospital outpatient revenue starting in 2027 and affecting roughly 3,500 hospitals and 6,400 ASCs. Device leaders should read the site-neutral expansion as a signal: as reimbursement flattens across care settings, the economics of where a procedure is performed — and who buys the device — are being rewritten. Comments close August 31.

Becker’s Hospital Review

5. ⚠️ Terumo initiates voluntary thoracic stent graft recall after 3 deaths

Terumo recalled roughly 7,000 RelayPro thoracic stent-grafts across 43 countries after four cases in which physicians couldn’t separate the delivery system from the deployed graft — three of which ended in patient deaths. Terumo hasn’t established direct causation but suspended shipments in March and has now expanded the action globally, a sharp reminder that delivery-system failures, not just the implant, sit squarely inside post-market risk.

MassDevice

6. 🔓 Major medical device manufacturer notifies nearly 4 million of breach

Medtronic began notifying nearly four million people that April’s ShinyHunters intrusion into its corporate IT systems exposed names, dates of birth, Social Security numbers, and health-related data — details that surfaced via a California AG notification filing. The company maintains device safety and operations were unaffected, but the notification scale underscores how patient-data liability now travels with any connected-device franchise, independent of clinical risk.

The Record

7. 🫀 Edwards Lifesciences crashes the LAA party — can the TAVR giant compete?

Edwards won 510(k) clearance for Ecliptis, its left atrial appendage exclusion clip, entering a crowded surgical LAA market against AtriCure’s AtriClip and Medtronic’s Penditure. Edwards is betting its structural-heart surgical relationships carry into a new therapeutic area — a textbook adjacency play whose success will hinge less on the device than on whether an established commercial channel actually transfers.

MD+DI

8. 🩸 Guardant’s Shield colon cancer blood test snags UnitedHealth coverage

UnitedHealth became the first major private U.S. insurer to reimburse Guardant’s Shield blood-based colorectal screening test, extending access to roughly 100 million people — a decision one analyst called a “watershed moment” for liquid biopsy. Notably, coverage arrived ahead of USPSTF inclusion, a reversal of the usual sequence that suggests commercial payers may increasingly move on category conviction rather than waiting for guideline consensus.

MedTech Dive

Put your brand in front of 35,000+ medical device and med tech leaders each week. Contact us to learn more about sponsorship opportunities.

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague who should be tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

The Fine Print on the Next Five Years

The medical device industry got its first look this week at the contract it will operate under through 2032. On Tuesday, the FDA posted the draft MDUFA VI commitment letter — the 36-page product of nearly a year of negotiations between the agency, AdvaMed, and the Medical Device Manufacturers Association over what industry user fees will buy in the sixth iteration of the device user fee program. The Federal Register notice followed Wednesday, opening a comment docket that closes July 29.

On paper, industry got much of what it asked for. The letter commits the agency to a new fast lane for pre-submission questions — written responses within 45 calendar days for focused follow-ups, launching by the end of 2027. De novo applicants would get a structured introduction meeting with reviewers inside the first 30 days of review. Major deficiency letters, a longstanding industry complaint, would require supervisory sign-off and a complete review before issuance. The TAP pilot graduates into a permanent program with hard metrics attached, including facilitated CMS engagement for devices that need new coverage determinations. And 510(k) decision targets start at an average of 128 calendar days for fiscal 2028 submissions, stepping down to 112 days by 2032.

The most quietly radical item is an international harmonization pilot slated for the end of fiscal 2028: a device submitted simultaneously to the FDA and at least two other regulatory authorities could get a coordinated review, with the agency leveraging elements of its counterparts’ assessments. The FDA retains final authority, and reliance is limited to an “abridged approach” — but an agency that has spent decades positioning itself as the global gold standard is now formalizing a mechanism to lean on other regulators’ work. That is a meaningful philosophical concession to resource reality.

Which is the tension running through the entire document. Every performance goal in the letter carries a conditional clause — the targets hold, the FDA writes, “provided that the total funding of the device review program adheres to the assumptions” underlying the agreement. That hedge is doing heavy lifting. This letter arrives at an agency that cut more than 3,000 roles last year and is now trying to hire 2,000, and it lands one week after BTIG data showed average PMA approval times reaching nearly 599 days in the first half — up from roughly 402 a year earlier. The agency is committing to move faster over the next five years at the precise moment its measured performance is moving in the other direction.

AdvaMed CEO Scott Whitaker welcomed the draft, framing it as delivering the stability and predictability innovators need. That’s the right corporate posture, and it’s also the industry’s real stake here: for companies planning submissions into 2028 and beyond, these targets are the planning assumptions that capital runways, launch calendars, and hiring plans get built on. A 128-day 510(k) average and a 45-day pre-sub lane are not abstractions — they’re inputs to every regulatory-timeline slide in every board deck for the next half decade.

The path from here is fixed: a public hybrid meeting on August 5, a final commitment letter to Congress by January 15, 2027, and enactment required by September 30, 2027, when MDUFA V expires. The window for the industry to shape the terms — or flag where the assumptions look shaky — is the next three weeks. After that, the fine print becomes the contract.

SPONSORED BY RŌG HEALTH

Where does your commercialization actually stand?
Two minutes to find out.

Device companies rarely fail on technology — they fail on sequencing. RŌG Health's free Commercial Readiness Check scores your readiness across six dimensions and shows where you're strongest and most exposed. If you want help closing a gap, it'll point you to the right starting place.

Take the Readiness Check →

Want to put your brand in front of 35,000+ medical device and med tech leaders each week? Contact us to learn more about advertising opportunities.

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

The throughline this week is a widening gap between what the FDA clears and what actually reaches patients. New mid-year data show device authorizations rising even as approval timelines stretch out; a STAT investigation puts hard numbers on how many “breakthrough” devices never make it to market; and a GAO probe flags recall oversight buckling under staff constraints. Meanwhile, the M&A machine keeps running — Zimmer’s tuck-in of Pacira’s iovera device shows strategics are still paying up for assets that fit a clear commercial channel, especially anything riding the non-opioid pain tailwind. The operator’s takeaway: clearance is table stakes; the real gating factors are timing, coverage, and post-market discipline.

8 things to watch this week:

1. 🧊 Zimmer Biomet to buy Pacira’s iovera pain device for up to $140M

Zimmer agreed to pay $70M upfront plus up to $70M in revenue-based milestones through 2031 for iovera, an FDA-cleared cryoneurolysis device that blocks pain by freezing targeted nerves. The deal slots neatly into Zimmer’s orthopedics channel and rides the tailwind of last year’s non-opioid pain legislation — a clean example of a strategic buying a commercial-ready asset that fits an existing salesforce rather than a moonshot.

MedTech Dive

2. ⏱️ FDA is authorizing more devices in 2026 — but taking longer to do it

A mid-year BTIG analysis found the FDA cleared more devices in the first half than a year ago, but average time to premarket approval ballooned to nearly 599 days from about 402. For smaller companies, that timing gap hits capital runway and demand forecasting harder than the approval itself — a reminder that “cleared eventually” and “cleared on schedule” are very different business cases.

MD+DI

3. 🧭 Most device companies don't fail on technology. They fail on sequencing.

Before you raise, launch a pilot, or scale revenue, small commercialization mistakes can cost months — or millions. RŌG Health's Commercial Readiness Check is a 2-minute diagnostic that shows whether your company is prepared for its next milestone, and points you to where the gaps are.

Take the Readiness Check →

Sponsored by RŌG Health

4. 🫀 What an abandoned heart-failure trial reveals about ‘breakthrough’ devices that never reach patients

STAT dug into LivaNova’s discontinued VITARIA vagus-nerve-stimulator trial to make a broader point: the majority of devices granted FDA breakthrough status are never authorized, and it’s rare to learn why. The piece is a useful corrective to the marketing shine around the breakthrough label — designation speeds review, but it’s no guarantee of a finish line, and the industry rarely gets to see the failures.

STAT

5. 🔍 GAO finds understaffed FDA putting some device recall work on the ‘back burner’

A Government Accountability Office report concluded the FDA’s recall oversight is beset by staffing shortfalls and slow response times, with the agency managing roughly 900–1,000 device recalls a year — three times the volume of drug or biologic recalls. GAO also flagged that the FDA hasn’t done fresh workforce planning amid ongoing departmental restructuring. For quality and regulatory leaders, it’s a signal that post-market timelines may get less predictable, not more.

Fierce Biotech

6. 💳 CMS and FDA roll out RAPID pathway to speed Medicare coverage for breakthrough devices

The administration unveiled a RAPID coverage pathway granting permanent Medicare coverage for qualifying breakthrough devices tied to IDE studies enrolling Medicare beneficiaries, while pausing the existing TCET program. CMS estimates roughly 40 devices could qualify now, with about 20 more eligible. Coverage-after-clearance has quietly become the industry’s bigger bottleneck than FDA review itself — this is the reimbursement side finally getting attention.

Fierce Healthcare

7. 📈 Medtech M&A holds its momentum after a decade-high 2025: PwC

PwC’s mid-year read found deal volumes and values tracking above the first half of 2025, powered by Boston Scientific’s Penumbra buyout and Danaher’s Masimo close — but with disclosed value concentrated in a handful of large transactions. The nuance worth flagging: as strategics scale, mid-size deals increasingly go undisclosed, so the visible headline numbers understate how broad the activity really is.

MedTech Dive

8. 🩸 FDA approves first gene therapy for young children with sickle cell disease

The agency cleared its first gene therapy indicated for young children with sickle cell disease, extending a one-time treatment approach into a pediatric population. It sits just outside the device lane, but it’s a marker worth tracking: the FDA’s willingness to push durable, high-cost one-time therapies into younger patients reshapes the coverage and durability questions that device makers in adjacent chronic-disease categories will face next.

FDA

Put your brand in front of 35,000+ medical device and med tech leaders each week. Contact us to learn more about sponsorship opportunities.

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague who should be tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.